Gut hormones as therapeutic agents in treatment of diabetes and obesity

被引：42

作者：

Tan, Tricia ^{[1
]}

Bloom, Stephen ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Div Diabet Endocrinol & Metab, Dept Investigat Med, London W12 0HS, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2013年 / 13卷 / 06期

基金：

英国生物技术与生命科学研究理事会; 英国医学研究理事会;

关键词：

GLUCAGON-LIKE PEPTIDE-1; HIGH-FAT DIET; GASTRIC BYPASS-SURGERY; FOOD-INTAKE; BARIATRIC SURGERY; ENERGY-EXPENDITURE; WEIGHT-LOSS; PANCREATIC-POLYPEPTIDE; INSULIN-RESISTANCE; EXENATIDE TWICE;

D O I：

10.1016/j.coph.2013.09.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Obesity and Type 2 Diabetes Mellitus (T2DM) present an ever-increasing threat to global health. Although bariatric surgery is an effective treatment, it cannot be applied to the vast majority of patients. The beneficial effects of bariatric surgery are related to complex alterations in the secretion of gut hormones. By recapitulation of the changes of gut hormone secretion after bariatric surgery, drugs based on gut hormones represent an exciting possibility for the treatment of T2DM and obesity. We review the rapidly emerging role of GLP-1 based treatments as well as the future for new drugs based on other gut hormones such as GIP, ghrelin, oxyntomodulin and peptide YY.

引用

页码：996 / 1001

页数：6

共 50 条

[1] Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, Kleopatra
Anyiam, Oluwaseun
Tan, Tricia
JOURNAL OF NEUROENDOCRINOLOGY, 2019, 31 (05)
[2] The impact of diabetes and obesity on fertility and the potential role of gut hormones as treatment
Sridhar, Ananyaa
Khan, Dawood
Moffett, R. Charlotte
DIABETIC MEDICINE, 2023, 40 (12)
[3] Gut hormones: Implications for the treatment of obesity
Neary, Marianne T.
Batterham, Rachel L.
PHARMACOLOGY & THERAPEUTICS, 2009, 124 (01) : 44 - 56
[4] Gut hormones: the future of obesity treatment?
McGavigan, Anne K.
Murphy, Kevin G.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (06) : 911 - 919
[5] GUT HORMONES AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH OBESITY AND DIABETES
Iantorno, M.
Campia, U.
Di Daniele, N.
Nistico, S.
Forleo, G. B.
Cardillo, C.
Tesauro, M.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2014, 27 (03) : 433 - 436
[6] The future role of gut hormones in the treatment of obesity
Troke, Rachel C.
Tan, Tricia M.
Bloom, Steve R.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2014, 5 (01) : 4 - 14
[7] Gut and hormones and obesity
Wren, Alison M.
OBESITY AND METABOLISM, 2008, 36 : 165 - 181
[8] Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery
Hoist, Jens Juul
CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (06) : 983 - 988
[9] Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy
Khoo, Bernard
Tan, Tricia Mei-Mei
JOURNAL OF ENDOCRINOLOGY, 2020, 246 (03) : R65 - R74
[10] Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, Gerald
Novikoff, Aaron
DiMarchi, Richard
Tschoep, Matthias H.
Mueller, Timo D.
COMPREHENSIVE PHYSIOLOGY, 2020, 10 (01) : 99 - 124

← 1 2 3 4 5 →